ImmunoGen Inc.
About ImmunoGen Inc.
ImmunoGen is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its proprietary antibody-drug conjugate (ADC) technology. The Company's lead product candidate, mirvetuximab soravtansine, is being advanced to Phase 3 testing for FRα-positive platinum-resistant ovarian cancer, and is also in Phase 1b/2 testing in combination regimens for earlier-stage disease. The Company's ADC technology is used in three other clinical-stage ImmunoGen product candidates, in Roche's marketed product, Kadcyla®, and in programs in development by partners Amgen, Bayer, Biotest, CytomX, Lilly, Novartis, Sanofi and Takeda.
593 articles with ImmunoGen Inc.
-
ImmunoGen Presents Final Overall Survival and Additional Efficacy Data from the SORAYA Trial at SGO Annual Meeting
3/25/2023
ImmunoGen, Inc. announced final overall survival data and an evaluation of sequence of therapy in the pivotal SORAYA trial of mirvetuximab soravtansine in patients with folate receptor alpha-high platinum-resistant ovarian cancer who had been previously treated with bevacizumab will be presented by Dr. Robert Coleman in a plenary session on Saturday, March 25, at the SGO 2023 Annual Meeting in Tampa, Florida.
-
ImmunoGen Reports Recent Progress and 2022 Financial Results
3/1/2023
ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financial results for the quarter and year ended December 31, 2022.
-
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 01, 2023
3/1/2023
ImmunoGen, Inc. announced that on February 28, 2023, the Compensation Committee of the Company’s Board of Directors approved, in aggregate, grants of non-qualified stock option awards to purchase 49,450 shares of its common stock and restricted stock units covering 15,200 shares of its common stock to three new employees under the ImmunoGen, Inc.
-
ImmunoGen Announces a Global, Multi-Target License and Option Agreement with Vertex for the Use of ImmunoGen's ADC Technology in the Development of Novel Targeted Conditioning Agents
3/1/2023
ImmunoGen, Inc., a leader in the expanding field of antibody-drug conjugates, announced a global, multi-target license and option agreement whereby it granted Vertex Pharmaceuticals rights to conduct research using ImmunoGen's ADC technology to discover novel targeted conditioning agents for use with gene editing.
-
ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences - February 22, 2023
2/22/2023
ImmunoGen, Inc. announced that the following presentations by Company management at upcoming investor conferences will be webcast: Cowen 43rd Annual Health Care Conference March 8 at 9:10am ET Barclays Global Healthcare Conference March 15 at 10:15am ET A webcast of each presentation will be accessible through the “Investors and Media” section of the Company’s website, www.immunogen.com.
-
ImmunoGen Announces Conference Call to Discuss Its 2022 Operating Results
2/15/2023
ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Wednesday, March 1, 2023 to discuss its 2022 operating results.
-
ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences - February 01, 2023
2/1/2023
ImmunoGen, Inc. announced that the following presentations by Company management at upcoming investor conferences will be webcast.
-
ImmunoGen Appoints Michael Vasconcelles, MD, as Executive Vice President, Research, Development, and Medical Affairs
1/4/2023
ImmunoGen, Inc. today announced that Michael Vasconcelles, MD, has been appointed Executive Vice President, Research, Development, and Medical Affairs.
-
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 04, 2023
1/4/2023
ImmunoGen, Inc. announced that on December 29, 2022, and in connection with the previously announced appointment of Michael J. Vasconcelles, MD as ImmunoGen’s Executive Vice President, Research, Development, and Medical Affairs, the compensation committee of the Company’s Board of Directors approved grants of non-qualified stock option awards to purchase 960,000 shares of its common stock under the ImmunoGen, Inc.
-
ImmunoGen Announces Susan Altschuller on FMLA Leave; Interim CFO Appointed
12/28/2022
ImmunoGen, Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, announced that Susan Altschuller, PhD, Senior Vice President and Chief Financial Officer, is on leave under the Family and Medical Leave Act and will not continue employment with ImmunoGen at the conclusion of her leave.
-
ImmunoGen Announces Webcast of Presentation and Q&A at the 41st Annual J.P. Morgan Healthcare Conference
12/27/2022
ImmunoGen, Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, announced that Mark Enyedy, President and CEO, will present at the upcoming 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CA. The presentation is scheduled for 3:45pm PT on January 10, 2023.
-
Biosion Announces Research Collaboration with ImmunoGen to Create Novel Antibody-Drug Conjugates
12/13/2022
Biosion USA, Inc., a global R&D biotechnology company, announced an exploratory research collaboration to create antibody-drug conjugates for the treatment of cancer with ImmunoGen, Inc., a leader in developing next generation ADCs.
-
ImmunoGen Presents Findings from Expansion Cohorts in Phase 1b/2 Study of Pivekimab Sunirine with Vidaza® and Venclexta® in Acute Myeloid Leukemia at ASH
12/10/2022
ImmunoGen, Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, announced initial safety and efficacy findings from dose-escalation and expansion cohorts of the Phase 1b/2 study of pivekimab sunirine in combination with Vidaza® and Venclexta® in patients with relapsed/refractory and frontline acute myeloid leukemia.
-
ImmunoGen entered into a clinical collaboration deal with Gilead Sciences Friday to evaluate the safety and efficacy of two drugs that, when used in concert, have the potential to treat AML.
-
ImmunoGen Announces Clinical Collaboration with Gilead to Evaluate Pivekimab Sunirine in Combination with Magrolimab in Relapsed/Refractory Acute Myeloid Leukemia
12/9/2022
ImmunoGen, Inc. today announced a clinical collaboration with Gilead Sciences, Inc. (Nasdaq: GILD) to evaluate the safety and anti-leukemia activity of pivekimab sunirine (pivekimab) in combination with magrolimab, a potential, first-in-class, investigational CD47 inhibitor, in patients with relapsed or refractory (R/R) CD123-positive acute myeloid leukemia (AML).
-
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 1, 2022
12/1/2022
ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on November 30, 2022, the compensation committee of the Company’s Board of Directors approved grants of non-qualified stock option awards to purchase an aggregate of 328,050 shares of its common stock (the “Employee Options”) to ten new employees under the ImmunoGen, Inc. Inducement Equity Incentive Plan.
-
ImmunoGen Appoints Daniel Char as Senior Vice President and Chief Legal Officer
11/21/2022
ImmunoGen, Inc. today announced that Daniel Char, JD, has been appointed Senior Vice President and Chief Legal Officer.
-
The FDA has a number of PDUFA dates for the remainder of November for Spectrum, ImmunoGen, Scynexis and Y-mAbs.
-
ImmunoGen's Elahere was approved Monday under the FDA's accelerated pathway for patients who have received one to three previous lines of systemic therapy.
-
ImmunoGen Announces FDA Accelerated Approval of ELAHERE™ (mirvetuximab soravtansine-gynx) for the Treatment of Platinum-Resistant Ovarian Cancer
11/14/2022
ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the US Food and Drug Administration (FDA) has granted accelerated approval for ELAHERE™ (mirvetuximab soravtansine-gynx) for the treatment of adult patients with folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens.